In 2012, the U.S. Food and Drug Administration (FDA) approved the use of the first-ever drug to protect against HIV in high-risk uninfected individuals. Studies showed that Truvada, when taken consistently, greatly reduced the risk of infection in men having sex with men and transgender women having sex with men, prompting one FDA panelist to say Truvada was “an amazing opportunity to turn the tide on this epidemic.”

Two years later, the number of Americans taking the pill is minute compared to the half-million who the Centers for Disease Control and Prevention (CDC) thinks could benefit from Truvada, otherwise known as pre-exposure prophylaxis or PrEP. Why has adoption been so slow? Read more at Monitor on Psychology